This week we are adding a biotech stock to our longer term venture portfolio. This is a German-listed company, which specialises in T cell immunotherapies, for the treatment of cancer. Biotech can be a high risk sector to invest in, of course, as investors are heavily reliant on the regulatory approval of treatments in development.
We like this company because it looks cheap right now, with a PE value of 6.2 and shares are well off the high they achieved back in 2021, when they could be had for EUR 4.00. Now they have slipped to almost half that. Analysts are bullish however: two analysts are currently covering the biotech stock, and the consensus is for an improvement in sales of +151% versus 2021.
The rest of this page is for members only. Please log in below or visit the registration page for Armchair Trader+ to see the benefits of becoming a member.
Log In or Sign Up to Armchair Trader+
Already a member? Log in here:
Not a member yet? Sign up for your free trial or check out the benefits of membership.
Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader+ for further details on the benefits of becoming a member.